Hence, upregulating GATA-3 and IL-4 expression and downregulating T-bet and IFN-γ levels may provide a novel therapeutic method for type 1 diabetes (T1D) treatment in non-obese diabetic (NOD) mice (30). This evidence concerns the gene GATA3 and type 1 diabetes mellitus.